APPLICATION OF INNOVATIVE MEDICINAL FORMS IN MODERN PHARMACOTHERAPY OF INFLAMMATORY DISEASES THROAT AND UPPER RESPIRATORY TRACTS

Abstract

The aim of the research is to justify the use of innovative dosage forms in modern pharmacotherapy of inflammatory diseases of the throat and upper respiratory tract. Research methods and materials. To conduct the research, the following methods were used: systematic and comparative analysis, generalization, statistical processing and synthesis to determine the predicted prospects for the use of innovative dosage forms in modern pharmacotherapy of inflammatory diseases of the throat and upper respiratory tract. The software and electronic resources of ATX (Anatomical-Therapeutically-Chemical), ATC (Anatomical Therapeutically Chemical Classification System), BSC (Biopharmaceutical Classification System), Vidal, Compendium, and the State Register of Medicinal Products of Ukraine were used to carry out the systematic and comparative analysis. Research results. Inflammatory diseases of the throat and upper respiratory tract are among the most common in the modern world. The effectiveness of pharmacotherapy prevents the occurrence of complications of these diseases and the economic costs of both the patient and health care institutions. In medical practice, the choice of the dosage form and its use determine the functional characteristics, the speed of development and the duration of the pharmacological effect, the spectrum of adverse reactions. The dosage form is a structural unit of pharmacotherapy and modern pharmaceutical production. According to the results of the study, the frequency of use of medicinal forms for the treatment of inflammatory diseases of the throat and upper respiratory tract according to the nomenclature of the State Formulary of aerosols and sprays is more than 50%; solid dosage forms – 36%, of which tablet preparations – 24%, granules and sachets for preparing solutions – 8.5%, liquid dosage forms – suspension and emulsion type solutions, syrups – 5.5%, lozenges, lozenges – 12%. In the segment of solid dosage forms, capsules make up 37%; tablets – 24%, granules and sachets for preparing solutions – 8.5%, orodispersible tablets – 12.5%, lozenges – 12%; medical fees -–5.95. Experimental and clinical studies have shown that the type of dosage form and the method of administration significantly affect the therapeutic effectiveness, determining the degree of its absorption and concentration in biological fluids. In modern medical practice, orodispersible tablets, as an innovative dosage form, are widely used to achieve an accelerated therapeutic effect by releasing active pharmaceutical ingredients in the oral cavity and affecting the mucous membranes of the oral cavity, throat and upper respiratory tract for the treatment of inflammatory processes. Orodispersible tablets are used both for local action and general action. Conclusions. The advantages of orodispersible tablets as a promising dosage form are: ease of use for such patients in pediatrics, geriatrics, and psychiatry; increased bioavailability as a result of dispersion in the oral cavity and rapid absorption; no need to drink water; pleasant taste; increased safety of use due to low risk of suffocation during medication administration. Regulatory requirements for the quality of pharmaceutical production of orodispersible tablets are distinguished by the fact that the term of disintegration and release of API must be clearly defined and acceptable for the availability of absorption in the oral cavity. From a regulatory point of view, the oral disintegration rate guidelines are currently being reviewed by the FDA, as these limits have been found to be limited for some orodispersible tablets that are firmly positioned in the pharmaceutical market. It has been established that with the development of industrial pharmacy, orodispersible tablets have become a promising pharmaceutical form for oral drug delivery systems.